Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement pathway‐regulatory protein

We describe the incidence of early graft failure (EGF, defined as loss of function from any cause within 3 days after transplant) in a large cohort of GalTKO pig organs transplanted into baboons in three centers, and the effect of additional expression of a human complement pathway‐regulatory protein, CD46 or CD55 (GalTKO.hCPRP). Baboon recipients of life‐supporting GalTKO kidney (n = 7) or heterotopic heart (n = 14) grafts received either no immunosuppression (n = 4), or one of several partial or full immunosuppressive regimens (n = 17). Fourteen additional baboons received a GalTKO.hCPRP kidney (n = 5) or heart (n = 9) and similar treatment regimens. Immunologic, pathologic, and coagulation parameters were measured at frequent intervals. EGF of GalTKO organs occurred in 9/21 baboons (43%). hCPRP expression reduced the GalTKO EGF incidence to 7% (1/14; P < 0.01 vs. GalTKO alone). At 30 mins, complement deposits were more intense in organs in which EGF developed (P < 0.005). The intensity of peri‐transplant platelet activation (as β‐thromboglobulin release) correlated with EGF, as did the cumulative coagulation score (P < 0.01). We conclude that (i) the transgenic expression of a hCPRP on the vascular endothelium of a GalTKO pig reduces the incidence of EGF and reduces complement deposition, (ii) complement deposition and platelet activation correlate with early GalTKO organ failure, and (iii) the expression of a hCPRP reduces EGF but does not prevent systemic coagulation activation. Additional strategies will be required to control coagulation activation.

[1]  E. Klein,et al.  Pig kidney graft survival in a baboon for 136 days: longest life‐supporting organ graft survival to date , 2015, Xenotransplantation.

[2]  R. Pierson,et al.  Meta‐analysis of the independent and cumulative effects of multiple genetic modifications on pig lung xenograft performance during ex vivo perfusion with human blood , 2015, Xenotransplantation.

[3]  Y. Takeuchi,et al.  Bortezomib, C1‐Inhibitor and Plasma Exchange Do Not Prolong the Survival of Multi‐Transgenic GalT‐KO Pig Kidney Xenografts in Baboons , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  R. Pierson,et al.  Development of a consensus protocol to quantify primate anti‐non‐Gal xenoreactive antibodies using pig aortic endothelial cells , 2014, Xenotransplantation.

[5]  Marvin L. Thomas,et al.  Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation. , 2014, The Journal of thoracic and cardiovascular surgery.

[6]  R. Wolf,et al.  Are there advantages in the use of specific pathogen‐free baboons in pig organ xenotransplantation models? , 2014, Xenotransplantation.

[7]  D. Ayares,et al.  Expression of Human CD46 Modulates Inflammation Associated With GalTKO Lung Xenograft Injury , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  R. Pierson,et al.  Transgenic Human Thrombomodulin Expression Reduces Xenogeneic Thrombosis: a Promising Means of Reducing Pig Lung Xenograft Thrombotic Injury , 2014 .

[9]  E. Wolf,et al.  Regulatory Sequences of the Porcine THBD Gene Facilitate Endothelial-Specific Expression of Bioactive Human Thrombomodulin in Single- and Multitransgenic Pigs , 2014, Transplantation.

[10]  Yifan Dai,et al.  The potential of genetically-engineered pigs in providing an alternative source of organs and cells for transplantation , 2013, Journal of biomedical research.

[11]  R. Pierson,et al.  Thrombin Generation and Platelet Activation in a Xenogenic Lung Perfusion Model Determine Survival of GalTKO.hCD46 Lungs , 2013 .

[12]  R. Pierson,et al.  Human EPCR Expression in GalTKO.hCD46 Lungs Extends Survival Time and Lowers PVR in a Xenogenic Lung Perfusion Model , 2013 .

[13]  S. Robson,et al.  Transgenic swine: expression of human CD39 protects against myocardial injury. , 2012, Journal of molecular and cellular cardiology.

[14]  H. Tazelaar,et al.  Human CD55 Expression Blocks Hyperacute Rejection and Restricts Complement Activation in Gal Knockout Cardiac Xenografts , 2012, Transplantation.

[15]  Ashutosh Kumar Singh,et al.  B‐Cell Depletion Extends the Survival of GTKO.hCD46Tg Pig Heart Xenografts in Baboons for up to 8 Months , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  K. Iwasaki,et al.  Production of cloned pigs expressing human thrombomodulin in endothelial cells , 2012, Xenotransplantation.

[17]  R. Bottino,et al.  Clinical xenotransplantation: the next medical revolution? , 2012, The Lancet.

[18]  R. Pierson,et al.  The Innate Immune Response and Activation of Coagulation in α1,3-Galactosyltransferase Gene-Knockout Xenograft Recipients , 2009, Transplantation.

[19]  H. Tai,et al.  In vitro investigation of pig cells for resistance to human antibody‐mediated rejection , 2008, Transplant international : official journal of the European Society for Organ Transplantation.

[20]  R. Pierson,et al.  Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes , 2007, Xenotransplantation.

[21]  T. Starzl,et al.  Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys , 2005, Nature Medicine.

[22]  D. Sachs,et al.  α1,3-Galactosyltransferase Gene-Knockout Pig Heart Transplantation in Baboons with Survival Approaching 6 Months , 2005, Transplantation.

[23]  Keiji Oi,et al.  Cardiac xenotransplantation : Recent preclinical progress with 3-month median survival , 2005 .

[24]  S. Robson,et al.  ACUTE VASCULAR REJECTION OF XENOGRAFTS: ROLES OF NATURAL AND ELICITED XENOREACTIVE ANTIBODIES IN ACTIVATION OF VASCULAR ENDOTHELIAL CELLS AND INDUCTION OF PROCOAGULANT ACTIVITY , 2004, Transplantation.

[25]  Kenneth G. C. Smith,et al.  Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts , 2003, Xenotransplantation.

[26]  S. H. A. Chen,et al.  Production of α1,3-Galactosyltransferase-Deficient Pigs , 2002, Science.

[27]  D. White,et al.  The generation of transgenic pigs as potential organ donors for humans , 1995, Nature Medicine.

[28]  R. Oriol,et al.  Genetically engineered pigs , 1993, The Lancet.

[29]  D. Cooper,et al.  Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. , 1992, Transplantation proceedings.

[30]  D. Hourcade,et al.  Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement , 1992, Transplant international : official journal of the European Society for Organ Transplantation.

[31]  J. Platt,et al.  Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. , 1991, Transplantation.

[32]  D. Sachs,et al.  Marked prolongation of porcine renal xenograft survival in baboons through the use of α1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue , 2005, Nature Medicine.

[33]  N. Mueller,et al.  Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience , 2005, Nature Medicine.